Episode 24: A Between the Biotech Waves conversation with John Hoffman, managing director & head of healthcare equity capital markets at Credit Suisse
Between the Biotech Waves
00:00
The Impact of Capital Redeployment on the Biotech Sector
There were some situations where I would say, well, you can actually link it back towards being heavily concentrated in the biotech dedicated funds that also invest in mid and midcap companies. And so that's very much a positive for the sector as you and I think about it. Do I say we saw a mixed outcome in that regard last year there were some white spots and there were some that were just engineered to have less of an impact on that capital redeployment opportunity.
Play episode from 23:30
Transcript
